Definition and Pathophysiology
Bradycardia encompasses a spectrum of rhythm disturbances characterized by an inappropriately slow heart rate. Within the context of acute coronary syndromes, particularly ST-elevation myocardial infarction (STEMI), ischemic injury can disrupt the conduction system at any level, producing atrioventricular (AV) or intraventricular blocks. Isolated sinus bradycardia in the early hours following infarction may be associated with hemodynamic compromise. More broadly, bradyarrhythmic arrest and asystole represent severe manifestations of impulse generation or conduction failure. The pathophysiology of these events may stem from reversible causes, including hypovolemia, hypoxia, cardiac tamponade, tension pneumothorax, preexisting acidosis, drug overdose, hypothermia, and hyperkalemia.
Clinical Presentation and Symptoms
The clinical manifestation of bradycardia depends on the adequacy of cardiac output. Isolated sinus bradycardia that is unaccompanied by hypotension or ventricular ectopy is generally asymptomatic and hemodynamically stable. However, when the sinus rate is extremely low—such as less than 40 to 50 beats per minute in the first 4 to 6 hours after an acute infarction—patients may develop hypotension and signs of end-organ hypoperfusion. In severe cases, bradycardia may progress to bradyarrhythmic arrest or pulseless electrical activity (PEA), presenting as cardiovascular collapse and cardiac arrest.
Evaluation and Physical Examination
The source material does not provide specific details regarding the physical examination or general evaluation of patients with bradycardia.
Diagnostics
Electrocardiographic assessment is fundamental to the diagnosis and management of bradyarrhythmias. In the setting of cardiac arrest, it is essential to reconfirm the rhythm in two leads if possible to distinguish true bradyarrhythmic or asystolic arrest from other tachyarrhythmic events. On the surface electrocardiogram, sinus bradycardia may appear at rates of 40 to 48 beats per minute, occasionally accompanied by junctional escape beats, which may present with P waves at the onset of the QRS complex. Nonrespiratory sinus arrhythmia may also be observed as a consequence of drug toxicity, such as digitalis excess.
Biomarkers and Laboratory Findings
The source material does not provide information on biomarkers or laboratory findings specific to the evaluation of bradycardia.
Treatment and Management, Including Acute and Long-Term Strategies
The initial approach to bradycardia management involves identifying and treating any underlying conditions or reversible causes. The first step in treating sinus bradycardia is to discontinue any medications that may be contributing to the slow rate. Acute treatment is generally unnecessary unless the cardiac output is inadequate, hypotension is present, or secondary arrhythmias result from the slow rate.
In the setting of bradyarrhythmic or asystolic arrest, management priorities shift to establishing control of cardiorespiratory status. This includes continuing cardiopulmonary resuscitation, performing intubation, and establishing intravenous access. Clinicians must promptly consider and exclude reversible causes, such as hypovolemia, hypoxia, tamponade, tension pneumothorax, acidosis, drug overdose, hypothermia, and hyperkalemia.
For recurrent symptomatic bradycardia, temporary or permanent pacing may be required. However, transcutaneous pacing in the setting of cardiac arrest has not demonstrated clear benefit. Long-term pharmacological management of chronic sinus bradycardia with a pacemaker is usually not necessary unless sinus rates are too slow to meet physiologic needs, such as during exercise (chronotropic incompetence). Although agents such as theophylline and terbutaline can increase the sinus rate, there are generally no reliable and safe drugs available for long-term heart rate augmentation without undesirable side effects.
Drugs, With Doses and Practical Considerations
Atropine
Atropine is the primary pharmacological agent for the acute treatment of symptomatic bradycardia. The recommended initial dose is 0.5 mg administered intravenously, repeated if necessary.
Practical considerations and limitations regarding atropine use include:
Dose-Dependent Effects: Lower doses of atropine, particularly when administered subcutaneously or intramuscularly, can exert an initial parasympathomimetic effect, possibly via a central action. Therefore, the intravenous route is preferred to avoid paradoxical bradycardia.
Acute Myocardial Infarction: In the first 4 to 6 hours after infarction, if the sinus rate is extremely low (less than 40 to 50 beats/min) and associated with hypotension, intravenous atropine can be administered. Isolated sinus bradycardia without hypotension or ventricular ectopy should be observed rather than treated.
Cardiac Arrest Limitations: Atropine is no longer considered of value for the management of PEA or asystole, although it may still be beneficial for other bradyarrhythmic mechanisms.
Alternative Agents in Bradyarrhythmic Arrest
When atropine is ineffective or in the setting of bradyarrhythmic arrest, alternative sympathomimetic agents may be employed to elicit spontaneous electrical activity or increase the rate of bradycardia:
| Drug | Dose and Route | Clinical Considerations |
|---|---|---|
| Epinephrine | 1 mg (10 mL of a 1:10,000 solution) intravenously, intracardiac, intraosseous, or endotracheal route. | Commonly used in arrest to elicit spontaneous electrical activity. Intracardiac administration carries a danger of coronary or myocardial laceration. The added value of high-dose epinephrine is unclear. |
| Isoproterenol | Up to 15 to 20 µg/min intravenously. | Has had only limited success in eliciting spontaneous electrical activity or increasing the rate of bradycardia. |
Inotropic and Vasopressor Agents
In cases where bradycardia is accompanied by shock or low cardiac output states, inotropic and vasopressor agents may be utilized. These agents increase intracellular cyclic adenosine monophosphate, leading to increased cytoplasmic calcium and augmented cardiac output.
| Drug | Clinical Indication | Dose Range | Receptor Binding (A1 / B1 / B2 / DA) | Major Side Effects |
|---|---|---|---|---|
| Dopamine | Shock (vasodilatory, cardiogenic); symptomatic bradycardia unresponsive to atropine or pacing | 2.0-20 (max 50) µg/kg/min | +++ / ++++ / ++ / +++++ | Severe hypertension, ventricular arrhythmias, cardiac ischemia, tissue ischemia/gangrene |
| Dobutamine | Low cardiac output; symptomatic bradycardia unresponsive to atropine or pacing | 2.0-20 (max 40) µg/kg/min | 1 / +++++ / +++ / N/A | Tachycardia, increased ventricular response rate in atrial fibrillation, ventricular arrhythmias, cardiac ischemia, hypotension |
| Norepinephrine | Shock (vasodilatory, cardiogenic) | 0.01-0.4 µg/kg/min | +++++ / +++ / ++ / N/A | Arrhythmias, bradycardia, peripheral (digital) ischemia, hypertension |
Guideline Recommendations
Guideline-directed recommendations emphasize a stepwise approach to bradycardia. For sinus bradycardia, withdrawal of offending medications and treatment of underlying conditions is the first step. Acute intervention with intravenous atropine (0.5 mg initial dose) is reserved for instances of inadequate cardiac output, hypotension, or secondary arrhythmias. In the context of STEMI, atropine is indicated only for extremely low rates associated with hypotension.
During cardiac arrest (PEA or asystole), guidelines prioritize cardiorespiratory support, rhythm reconfirmation, and the exclusion of reversible causes. Atropine is explicitly not recommended for PEA or asystole. Epinephrine remains the primary pharmacological intervention in this setting, though its success is limited. Transcutaneous pacing has not shown clear outcome benefits in arrest scenarios.
Prognosis and Follow-Up
The source material does not provide specific data regarding the long-term prognosis or follow-up strategies for patients treated with atropine for bradycardia.
